Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Notebook: Moderna Renounces COVID-19 Patents, China Joins COVAX

Executive Summary

The CEPI coalition plans a global network to assess and compare the immunological responses generated by COVID-19 vaccine candidates, and a trial gets under way to test whether the BCG vaccine can afford some immunity against coronavirus.

You may also be interested in...



Coronavirus Notebook: EU Strikes Deals For Gilead’s Veklury, Janssen’s Vaccine

Russia is planning to register a second COVID-19 vaccine this month, while the UK is ramping up its manufacturing capacity for vaccines and therapeutics. 

Second COVID-19 Vaccine Undergoes ‘Rolling Review’ By EMA

The European Medicines Agency is fast-tracking its review of the vaccine that BioNTech and Pfizer are developing and testing in Phase III trials.

Global Coalition Urges Regulatory Convergence On COVID-19 Vaccines

Mutual recognition of approvals and simplified rules on labeling could help to make COVID-19 vaccines more accessible to populations around the world. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134361

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel